Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Varian adds neurosurgery expert to team

This article was originally published in Clinica

Executive Summary

Cancer therapy specialist Varian Medical Systems has made John Adler its vice-president and chief of new clinical applications. Dr Adler is a neurosurgeon and professor of neurosurgery and radiation oncology at Stanford University, and will help Varian to develop its next-generation clinical products and applications for radiosurgery and other new treatments. He will join the Palo Alto, California-based firm on April 5. Dr Adler was formerly the CEO, chairman and founder of radiosurgery company Accuray, where he served from 1991 until 2009. Varian claims to be the “world's leading manufacturer of radiotherapy and radiosurgery solutions”, and through a collaboration with BrainLAB, a manufacturer of software-driven medical technology, it has developed the Novalis Tx radiosurgery platform, a non-invasive system for the treatment of tumours and other anatomical targets.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT053862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel